Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Key Who May Qualify: - Has been diagnosed with relapsed/refractory AML. - Has a documented NPM1 mutation or KMT2A rearrangement. - Has a documented FLT3 mutation (cA-3 only). - Has an Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2. - Has adequate hepatic and renal function as defined per protocol. - Has an ejection fraction above a protocol defined limit. - Participant, or legally authorized representative, must be able to understand and provide written willing to sign a consent form prior to the first screening procedure. - Has agreed to use contraception as defined per protocol. Key Who Should NOT Join This Trial: - Has a diagnosis of acute promyelocytic leukemia or blast chronic myeloid leukemia. - Has clinically active central nervous system leukemia. - Has an active and uncontrolled infection. - Has a mean corrected QT interval (QTcF) \> 480ms. - Has uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease. - Has received radiation, chemotherapy, immunotherapy, or any other anticancer therapy including investigational therapy \<14 days or within 5 drug half-lives prior to the first dose of study intervention. - Has had major surgery within 4 weeks prior to the first dose of study intervention. - Has received a hematopoietic stem cell transplant (HSCT) and has not previously had adequate recovery per protocol defined criteria. - Has active graft-versus-host disease (GvHD) and or on immunosuppressive drugs for the treatment of GvHD - Participant is pregnant or lactating. Always talk to your doctor about whether this trial is right for you.